More stories
PT316 – Lenny Gibson, Ph.D. – Vital Psychedelic Conversations
In this episode of Vital Psychedelic Conversations, David Drapkin interviews philosopher, clinical psychologist, Grof-certified Holotropic Breathwork® facilitator, and Co-Founder of Dreamshadow Group: Lenny Gibson,...
Hallucinating Long After the Trip is Over: HPPD – Part 2
Psychedelics are going mainstream, with news features proclaiming they may hold the promise to heal trauma, offer alleviation from depression and anxiety, and the...
PT315 – Dr. Dominique Morisano – From Research to Reality: Planning a Global Psychedelic...
In this episode of the podcast, David Drapkin interviews Dr. Dominique Morisano: clinical psychologist, professor, researcher, and Co-Founder of the upcoming non-profit conference, "From...
Psilocybin Alpha is now Psychedelic Alpha
A note from Josh Hardman… It’s been over two years since I launched Psilocybin Alpha. As I mentioned in our 2021 Year in Review,...
PT314 – Daniel McQueen, MA – Vital Psychedelic Conversations
In this episode of Vital Psychedelic Conversations, Kyle Buller interviews Daniel McQueen, MA: author of “Psychedelic Cannabis: Therapeutic Methods and Unique Blends to Treat...
Hallucinating Long After the Trip is Over: HPPD – Part 1
Psychedelic clinical trials are on the rise and more are on the way as previous studies have generally concluded that psychedelics are safe. Researchers...
Psychedelics Today Has Hit 3 Million Downloads!
By Victoria Dekker and Mike Alexander This week, we celebrated a humbling achievement at Psychedelics Today: three million unique downloads of the Psychedelics Today...
Psychedelic Bulletin: Psychedelics X Big Pharma; $23m Round for At-Home Ketamine Therapy; Psychedelics Research...
This Week: Psychedelics startup X big pharma licensing deal At-home ketamine therapy company scores $23m Series A Psychedelics Research Review (March 2022) 2 events...
Psychedelic Research Bulletin: March 2022
As the first quarter of 2022 came to a close we continue to discover more about psychedelics and their apparent therapeutic potential. March was...
MYND Life Sciences Announces $3.5 Million Share Offering
Vancouver, British Columbia–(Newsfile Corp. – April 21, 2022) – MYND Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF)(“MYND” or the “Company“), is pleased to announce...
Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for...
TORONTO–( BUSINESS WIRE)– Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that...
COMPASS Pathways partners with One Mind to fund Rising Star Awards for the next...
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced...
